Abstract
Introduction: PURE, an international, prospective, observational study from Canada and Latin America, assesses real-world safety and effectiveness of secukinumab in patients with moderate to severe psoriasis (PsO) vs other approved therapies. This abstract describes clinical outcomes from an interim analysis in secukinumab-treated group, stratified by prior biologic experience over 30 months (M30) of treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
